TRIAL DETAIL
FR901228 in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
FR901228 in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma |
|||
NCT#: |
||||
Conditions: |
GIST
Sarcoma |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 12/01/2005 |
Age of Trial (yrs) 19 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
HDAC inhibitor |
|||
Strategy: |
Destroy KIT + Unblock cell death genes |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
CDR0000433042, CCCWFU-71103 |
|||
Sponsor: |
Wake Forest University
NCI
|
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
IV
Intravenous |
|||
Trial Notes: |
A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas This drug is an HDAC inhibitor. |
|||
Trial Links |
Trial Results |
Drug Information |
| FDA prescribing information |
| Romidepsin in Wikipedia |
| Istodax.com |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
2880 N. Monroe |
Decatur |
IL |
62526 |
USA |